Who this combination is designed for

For many patients reaching KL Grade III or IV on their knee scan, the question is not whether there is damage — the imaging makes that plain — but whether anything meaningful can still be done before a joint replacement becomes inevitable. When that scan also shows evidence of synovial thickening or fluid, and the clinical picture includes rest pain, recurrent swelling, or inflammatory flares on top of the structural wear, a single injection is often not enough to address what is actually happening inside the joint.

By the time osteoarthritis reaches this stage, damage has typically accumulated at two anatomically distinct sites. The articular cartilage on the load-bearing bone surfaces has thinned or broken down; separately, the synovial membrane lining the joint capsule has become irritated and inflamed. These are not the same problem. One drives mechanical deterioration; the other drives the inflammatory cycle of pain and swelling. Treating only one while leaving the other active is a recognised limitation of single-modality injection approaches.

A combination treatment targeting both sites simultaneously is therefore indicated for a specific patient profile: a worn, inflamed knee in someone who wants to preserve the joint and postpone or avoid replacement, rather than anyone with general knee pain or early-stage OA. Suitability is determined through a structured MRI-led clinical assessment — the degree and pattern of cartilage loss, the presence and character of synovitis, and the overall joint architecture all factor into whether this pathway is appropriate.

Why two injections rather than one

The distinction between these two products matters mechanistically, not just anatomically.

ChondroFiller is an acellular injectable collagen scaffold — Type I collagen that polymerises in situ when placed onto a worn articular surface. Its mechanism is acellular matrix-induced chondrogenesis: the scaffold creates a structured environment that recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, drawing them into the matrix where they begin differentiating to support the body's own cartilage repair processes. No donor cells are implanted. The collagen acts as an architectural guide; the patient's biology does the work — a process that unfolds progressively over six to twelve months.

Arthrosamid operates through an entirely different pathway. It is a 2.5% polyacrylamide hydrogel that integrates into the synovial membrane rather than sitting on the cartilage surface. Within ten to fourteen days of injection, synovial cells begin invading the gel; by approximately thirty days in some models, a stable sub-synovial layer has formed — vascularised and covered by regenerated synovial lining facing the joint cavity. The result is a durable cushioning effect and a reduction in mechanical irritation to the inflamed membrane, through a process that has nothing to do with cartilage scaffolding.

These are not variants of the same treatment. ChondroFiller is the regenerative, scaffold-based component; Arthrosamid is a non-regenerative hydrogel acting at a structurally separate site. Collapsing them into a single category of 'joint filler' misrepresents both the science and the clinical rationale for using them together.

ChondroFiller's clinical evidence in the knee

The clinical record for ChondroFiller in the knee draws on four prospective studies, and the outcome pattern is consistent. IKDC scores — the validated patient-reported measure of knee function — improved by approximately 30 points across each. The threshold clinicians use to define a meaningful change is 16.7 points; roughly twice that was achieved on average.

The most detailed dataset comes from Jerosch et al., a post-market clinical follow-up study tracking patients to three years. Mean IKDC improvement reached 32.4 points at that point, with patients arriving at a functional score of 80 — a level reflecting an active, well-functioning knee rather than symptom reduction alone. Three-year durability is a relevant anchor for anyone weighing how long a non-surgical pathway might hold.

MRI adds a structural dimension to the functional data. MOCART scores — a standardised measure of repair tissue quality — rose from 65.3 at four weeks to 81.6 at twelve months, reaching 81.6 to 84.3 across available European studies. That range indicates more than 80% defect filling with good integration into surrounding native cartilage; the trajectory matters as much as the endpoint, since structural maturation continues progressively across the first year.

External peer-reviewed corroboration comes from Demmer et al. (2025, PMC), who studied ChondroFiller in wrist cartilage defects. Treated patients showed statistically superior cartilage quality versus controls on both Outerbridge grading (median 1.5 vs 3.0, P=0.006) and ICRS scoring (1 vs 3, P=0.002). The knee outcomes stand independently on their own evidence base; the wrist findings are relevant because an independent group, working in a different joint, found the same scaffold mechanism producing measurable cartilage improvement — confirming this is not an effect tied to a single trial setting or clinical centre.

Arthrosamid's role in the synovial compartment

Within the CFI+ protocol, Arthrosamid occupies a specific and bounded role: addressing the synovial environment that ChondroFiller, placed onto the cartilage surface, cannot reach.

The integration pathway described in section two — macrophage-mediated synovial cell invasion, stable sub-synovial layer formation within thirty to ninety days, persistence of up to two years in animal models — translates clinically into durable symptom reduction. Published data document significant pain reduction to five years post-injection, which in the combination context means the anti-inflammatory synovial effect is likely to outlast the period of ChondroFiller scaffold maturation and early cartilage repair.

An additional signal comes from the London Cartilage unit's own published research. Maulana, Cole and Lee (2022) reported reductions in patellofemoral bone marrow lesions following a single iPAAG injection in patients with advanced knee osteoarthritis — an imaging finding that suggests an effect at a structural level beyond pain modulation. This is one study, and bone marrow lesion reduction should not be read as evidence of cartilage restoration; Arthrosamid is not a regenerative therapy and does not repair articular cartilage. What the finding does support is the premise that modifying the synovial environment may have consequences extending into adjacent bone, which strengthens the rationale for addressing both compartments simultaneously rather than the cartilage surface alone.

What the combined treatment session involves

Both injections are placed in a single outpatient appointment under continuous ultrasound guidance — no theatre, no general anaesthetic, and no surgical wound to recover from. The clinician places 2.3 mL of ChondroFiller directly onto the worn articular cartilage surfaces, then introduces 6 mL of Arthrosamid to integrate with the synovial lining; each product is directed to its own anatomical target within the same session.

The guide cost for this dual-injection protocol is £6,000, confirmed by the treating clinic. For patients with more complex presentations — where the structural and synovial picture suggests that a regenerative scaffold and synovial modulation may not be sufficient on their own — a three-component pathway incorporating autologous mesenchymal stem cells is available at a guide cost of £11,000. That extended option is not the default; it is indicated for cases where cellular signalling is considered a meaningful additional contribution alongside the other two agents.

For patients who proceed, the clinic offers a long-term monitoring arrangement that includes annual MRI to track structural change over time and periodic ChondroFiller top-up injections, alongside adjunct peptide support. This is optional, but the annual imaging in particular reflects the fact that cartilage repair at this stage of disease benefits from objective surveillance rather than symptom-driven review alone.

Neither ChondroFiller nor Arthrosamid is funded by the NHS, and neither is currently covered by major UK private insurers such as Bupa or AXA. Treatment is entirely self-funded — something patients need to factor into their planning from the outset.

Evidence gaps, candidacy limits, and next steps

The most important caveat to state plainly: no published randomised controlled trial or prospective cohort study has evaluated ChondroFiller and Arthrosamid as a combined intervention. The clinical rationale for pairing them draws on each product's independent evidence record, but the combination as an entity has not been tested under controlled conditions. That gap does not invalidate the mechanistic argument; it is, however, information a patient should hold alongside the outcome data presented in earlier sections.

Candidacy is not determined by KL grade alone. The CFI+ protocol is positioned primarily at KL Grade III and IV, yet some practitioners apply ChondroFiller across Grade II–III as well — grade is an input to assessment, not a fixed threshold. The more clinically relevant question is whether imaging confirms both articular surface loss and active synovial pathology. Where only one is present, a single-component pathway may be more appropriate than the combination.

ChondroFiller is not a universal substitute for knee replacement in advanced osteoarthritis. Joints where the anatomical damage is too extensive, or where mechanical alignment is significantly compromised, may not provide the conditions the collagen scaffold requires to function. That determination depends on MRI-led assessment and clinical examination — not symptom reporting alone.

For patients seeking that review, London Cartilage Clinic on Harley Street — where Professor Paul Y. F. Lee leads cartilage-specialist assessment — can be reached via londoncartilage.com. What the consultation ultimately addresses is not whether the combination is coherent in principle, but whether this particular joint, at this particular stage of disease, is one the current evidence would support treating this way.